BLL Separation Collapsed Before Outcomes Were Measured

The TLC trial achieved its largest blood lead separation in the first week of treatment. From that point forward, the gap between succimer and placebo groups narrowed steadily. The following values are derived from Rogan et al. (2001, Figure 1) and TLC Group (2000, Figure 1):

By the time IQ was measured at 36 and 60 months, both groups had equilibrated to the same blood lead levels. Rogan et al. (2001) report these trajectories in Figure 1, showing near-complete convergence by 30 weeks.

Mean peak blood lead level post-randomization was 30.6 µg/dL (Chen et al. 2005, Table 1), exceeding the 26.2 µg/dL baseline mean reported by Rogan et al. (2001, Table 1). This confirms that children were immediately re-exposed after chelation, and the drug’s effect was overwhelmed by ongoing environmental lead exposure.

Both treatment arms experienced this post-randomization spike. Chen et al. (2005) report the peak occurred at a mean age of 2.2 ± 0.7 years — approximately 2.4 months post-randomization, while succimer was still being administered.

Section 4.7 of the TLC Protocol (Version 10, November 4, 1997) acknowledged environmental re-exposure as a known competing explanation for treatment failure. It described a planned analysis to distinguish whether a null finding reflected drug inefficacy or was attributable to re-exposure after chelation.

This analysis was never published. No TLC publication distinguishes between the hypothesis that succimer does not work and the hypothesis that succimer works but its effect was erased by re-exposure.

The TLC Group (1998) powered the trial to detect a 3-point IQ difference based on a sustained 10 µg/dL separation between groups. A sustained 10 µg/dL separation appears to have occurred for only a few weeks at the beginning of treatment, based on the BLL trajectories reported by the TLC Group (2000, Figure 1).

By the time cognitive outcomes were assessed, there was no difference in blood lead levels between the treatment and placebo groups (Rogan et al. 2001, Figure 1). The trial therefore tested a fundamentally different hypothesis than whether sustained BLL reduction improves cognition — it tested whether a transient, past reduction produces lasting cognitive benefit years after the drug effect has vanished.

Rogan et al. (2001) state: “Our study was designed to have 82 percent power to detect a difference of 3 points between the treatment groups.” But a 3-point difference requires a sustained exposure difference that the trial did not achieve.

The TLC trial is cited as proof that chelation does not improve cognition in lead-exposed children. But the drug’s measurable effect on blood lead levels had completely vanished before IQ was ever measured. What was actually tested was not whether lowering blood lead improves cognition, but whether having once had lower blood lead — years ago, for a few weeks — leaves a lasting cognitive imprint.

This distinction is not academic. It determines whether the trial’s null finding means succimer does not work, or whether it means a transient reduction without environmental remediation is insufficient. The protocol’s own Section 4.7 acknowledged this ambiguity and proposed an analysis to resolve it. That analysis was never published.

Whether sustained BLL reduction — achieved through chelation combined with environmental intervention — would improve cognitive outcomes in lead-exposed children remains an untested hypothesis. See also: Statistical Power Claims, Effect Size Estimate.